SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03306680|
Recruitment Status : Recruiting
First Posted : October 11, 2017
Last Update Posted : February 18, 2021
This multi-centre phase I dose-escalation study will use a time-to-event continual reassessment method (TIT-CRM).
Accrual will start at level 1 (60 Gy in 8 fractions). Patients will be assigned to treatment doses using the TITE-CRM model. The model will use all available information from previously accrued patients to assign the highest dose with a predicted risk of grade 3 toxicity of 30% or less.
|Condition or disease||Intervention/treatment||Phase|
|Non Small Cell Lung Cancer||Radiation: SBRT||Phase 1|
This study will use a time-to-event continual reassessment method (TITE-CRM). The study design is based on RTOG 0813 (described above), but with a more cautious approach, since the patients herein may constitute a high-risk subset of the patients enrolled in RTOG 0813. The modifications include a starting dose (60 Gy in 8 fractions) herein that is lower than the safe dose for central tumors as determined by RTOG 0813 (60 Gy in 5 fractions), and longer follow-up period during which patients are considered at-risk for toxicity, (i.e. two years herein vs. one year in RTOG 0813).
The primary endpoint of this study is the maximally tolerated dose (MTD) of radiotherapy for ultracentral tumors. The MTD is the dose of radiotherapy associated with a <30% rate of grade 3-5 toxicity occurring within 2 years of treatment.
Local Progression, Regional nodal progression, Distant metastases, Progression-Free Survival, Overall survival, patient reported outcomes and quality of life.
The correlative objectives of this study are to determine the prognostic value of ctDNA levels measured pre-treatment, at the end of treatment and 3- and 12-months after treatment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial|
|Actual Study Start Date :||January 19, 2018|
|Estimated Primary Completion Date :||October 2022|
|Estimated Study Completion Date :||October 2022|
Experimental: Patients with ultra-central NSCLC T1-3 (<6cm) N0 M0
Level-1 Dose per fraction: 4Gy Number of fractions: 15 Total Dose: 60 Gy
Level 0 Dose per fraction: 6Gy Number of fractions: 10 Total Dose: 60 Gy
Level 1 Dose per fraction: 7.5 Gy Number of fractions: 8 Total Dose: 60 Gy
Patients will be assigned to treatment doses using the TITE-CRM model.
- Maximally tolerated dose (MTD) [ Time Frame: Occurring within 2 years of treatment ]MTD of radiotherapy for ultracentral tumors. The MTD is the dose of radiotherapy associated with a <30% rate of grade 3-5 toxicity occurring within 2 years of treatment.
- Time to Local Progression [ Time Frame: 3-5 years ]
- Regional nodal progression [ Time Frame: 3-5 years ]Defined as presence of enlarged lymph nodes >1 cm [short axis] in the hilum or mediastinum.
- Time to distant metastases [ Time Frame: 3-5 years ]
- Progression-Free Survival [ Time Frame: 3-5 years ]
- Overall survival [ Time Frame: 3-5 years ]
- Patient reported outcome [ Time Frame: Before treatment & at 3, 6, 9, 12, 18, 24, 36, 48, and 60 months ]FACT-L
- Quality of Life [ Time Frame: Before treatment & at 3, 6, 9, 12, 18, 24, 36, 48, and 60 months ]EQ-5D-5L
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03306680
|Contact: David Palma, MDemail@example.com|
|Contact: Meredith Giuliani, MBBS, FRCPCfirstname.lastname@example.org|
|Canada, British Columbia|
|BC Cancer -Vancouver Island||Recruiting|
|Vancouver, British Columbia, Canada, V8R 6V5|
|Contact: Sarah Irons 250-519-5423 ext 695423 email@example.com|
|Contact: Samual Hackett Samuel.Hackett@bccancer.bc.ca|
|Principal Investigator: Tanya Berrang, FRCP|
|London Regional Cancer Program||Recruiting|
|London, Ontario, Canada, N6A 4L6|
|Contact: Anne O'Connell 519-685-8618 firstname.lastname@example.org|
|Contact: James Sinfield 519-685-8618 email@example.com|
|Principal Investigator: David Palma|
|Sunnybrook Odette Cancer Centre||Recruiting|
|Toronto, Ontario, Canada, M4N 3M5|
|Contact: Ilda Carvalhana 416-480-5000 Ilda.Carvalhana@sunnybrook.ca|
|Principal Investigator: Alexander Louie, FRCPC|
|Princess Margaret Cancer Centre||Recruiting|
|Toronto, Ontario, Canada, M5G 1X6|
|Contact: Meredith Giuliani, MD, FRCPC 416-946-2853 Meredith.Giuliani@rmp.uhn.ca|
|Contact: Lea Dungao 416 946 4501 Lea.Dungao@rmp.uhn.ca|
|Centre Hospitalier de l'Universite de Montreal (CHUM)||Recruiting|
|Montréal, Quebec, Canada, H2X 0A9|
|Contact: Diane Trudel, RN 514-890-8000 ext 26906 firstname.lastname@example.org|
|Principal Investigator: Edith Filion, MD FRCPC|
|McGill University Health Centre-Cedars Cancer Centre||Recruiting|
|Montréal, Quebec, Canada, H4A 3J1|
|Contact: Marianna Perna,, CCRC, CCRP, CHM, DIPBA (514) 934-1934 ext 43191 email@example.com|
|Principal Investigator: Sergio Faria, FRCPC|
|Saskatoon Cancer Centre||Recruiting|
|Saskatoon, Saskatchewan, Canada, S7S 0B1|
|Contact: Charmi Patel, CCRP 306-655-2714 Charmi.firstname.lastname@example.org|
|Principal Investigator: Vijayananda Kundapur, FRCR|
|Principal Investigator:||Meredith Giuliani, MBBS, FRCPC||Princess Margaret Cancer Center|